Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    "Neurofibromatosis type 2"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Endostatin
2 Recruiting Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas
Intervention: Drug: Axitinib
3 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
4 Completed Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Conditions: Acoustic Schwannoma;   Neurofibromatosis Type 2
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
5 Recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
6 Completed
Has Results
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib
7 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
8 Completed
Has Results
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
9 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
10 Suspended PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Intervention: Drug: PTC299
11 Recruiting AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Conditions: Neurofibromatosis 2;   Meningioma
Intervention: Drug: AZD2014
12 Completed An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Condition: Neurofibromatosis 2
Intervention: Device: Penetrating auditory brainstem implant
13 Recruiting Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Conditions: Vestibular Schwannoma;   Meningioma;   Acoustic Neuroma;   Neurofibromatosis Type 2
Intervention: Drug: AR-42
14 Active, not recruiting Natural History Study of Patients With Neurofibromatosis Type 2
Conditions: Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
Intervention:
15 Unknown  NF2 Natural History Consortium
Conditions: Schwannoma, Vestibular;   Neurofibromatosis 2;   Meningioma
Intervention:
16 Unknown  Effect of Implant Position on Magnetic Resonance Image Distortion
Condition: Neurofibromatosis Type 2
Intervention: Device: MR imaging
17 Recruiting Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention: Drug: RAD001
18 Active, not recruiting Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
19 Not yet recruiting Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Condition: Neurofibromatosis 2
Interventions: Behavioral: Stress Management Group 1;   Behavioral: Stress Management Group 2
20 Completed Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
Condition: Neurofibromatosis 2
Intervention: Device: Multichannel Auditory Brain Stem Implant

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Indicates status has not been verified in more than two years